Fucosylation of antibodies in multi-inflammatory syndrome in children after SARS-CoV-2 infection

Fucosylation of antibodies in multi-inflammatory syndrome in children after SARS-CoV-2 infection - FLAMINGO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54254

Enrollment

120

Registered

2021-01-18

Start date

2021-01-14

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid inflammatory disease

Interventions

None listed

Eligibility

Age

No minimum to 17 Years

Inclusion criteria

Inclusion criteria: Children 0-16 years of age with a laboratory confirmed COVID-19 (RIVM) and MIS-C.

Exclusion criteria

Exclusion criteria: Severe immune-related comorbidity (humoral immunodeficiency, cellular immunodeficiency, treatment for cancer, treatment with biologicals, IVIG treatment at moment of inclusion).

Design outcomes

Primary

Measure	Time frame
Fucosylation of SARS-CoV-2 IgG antibodies defined as percentage of fucose-containing glycans attached to N297 in the IgG-Fc. Focus will be on the main subclass generated (IgG1 and IgG3).	—

Secondary

Measure	Time frame
We compare the anti-CoV antibody response and interaction with immune receptors between cases and controls by: - Anti-CoV antibody levels, (sub)class and antigen specificity (ELISA) - Anti-CoV antibody glycosylation - Interaction of serum-derived patient anti-CoV antibodies with a biosensor equipped with all human Fc-gamma receptors - Inflammatory markers of juvenile idiopathic arthritis (see UCAN CAN-DU protocol) -To study gene expression profiles to distinguish between inflammatory and infectious causes of fever.	—

Measure

Time frame

We compare the anti-CoV antibody response and interaction with immune receptors between cases and controls by: - Anti-CoV antibody levels, (sub)class and antigen specificity (ELISA) - Anti-CoV antibody glycosylation - Interaction of serum-derived patient anti-CoV antibodies with a biosensor equipped with all human Fc-gamma receptors - Inflammatory markers of juvenile idiopathic arthritis (see UCAN CAN-DU protocol) -To study gene expression profiles to distinguish between inflammatory and infectious causes of fever.

—

Countries

Netherlands

Outcome results